patient | Page 8 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

patient

  1. Home

BEXMAB Study: Dr. Amer Zeidan Remarks on the Results’ Meaning for MDS Care

Amer Zeidan, MBBS, MHS, is professor of internal medicine at Yale School of Medicine in New Haven, Connecticut. He is also the chief of the Division of Hematologic Malignancies at Yale Cancer Center, New Haven.

Dr. Zeidan spoke with Blood Cancers Today about the phase 1/2 BEXMAB study, which was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, recently held in Chicago, Illinois, and will be presented at the European Hematology Association (EHA) 2025 Congress in Milan, Italy.

Very long-term remission with azacitidine in VEXAS syndrome

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly identified monogenic disorder with symptoms including recurrent fever, skin involvement, pulmonary infiltrates, systemic vasculitis, and chondritis.1 Notably, 25-50% of patients also have myelodysplastic syndrome (MDS). VEXAS syndrome often requires high-dose steroids and is resistant to standard immunomodulatory agents.

Allen’s Journey with Aplastic Anemia, Part 1

Person's Name: 
Allen Davis

Allen had a gratifying life.  He had a wife and a two-year-old, living on a farm, working in the Post-Anesthesia Care Unit at the teaching hospital.  He exercised, ran, hiked, hunted, fished, and more, enjoying the outdoors, his family, and his career.

In January, he had the worst case of the flu he had ever experienced.  The 104-degree fevers lasted several days.  He recovered enough to travel to Europe on a scheduled family trip, finally feeling up to a 10-mile hike at the end of the visit.

Bone Marrow Disease(s): 
Content source: 
web exclusive